Clinical trials: Aripiprazole, completed
Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and…
- Trial name
- ASPIRE (NCT01129882)
- Testing
- Aripiprazole
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 709 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dopamine Receptor Occupancy, Medication Satisfaction
Validation of Receptor Occupancy Simulation
To estimate dopamine receptor occupancy by aripiprazole using computer simulation To measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics To validate the simulation result by comparing…
- Conditions
- Dopamine Receptor Occupancy, Medication Satisfaction, Prolactin Level, Schizophrenia
- Trial name
- NCT01660880
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Seoul National University Hospital
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder
The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.
- Trial name
- NCT00257972
- Testing
- aripiprazole
- Where
- 90 sites in United States, Australia and 15 more
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alcohol Dependence
An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence
The principal aim of this exploratory study is to examine whether the addition of aripiprazole to naltrexone will enhance efficacy over naltrexone alone in a 16-week randomized, placebo-controlled clinical trial, in which all…
- Trial name
- NALAPZ (NCT00667875)
- Testing
- Naltrexone, Naltrexone + Aripiprazole
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Medical University of South Carolina
Bipolar I Disorder
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
To assess the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner in patients with Bipolar I Disorder experiencing a manic or mixed…
- Trial name
- NCT00606229
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Bipolar Depression
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.
- Trial name
- NCT00363337
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Lindner Center of HOPE
Bipolar Disorder
An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder
This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current medications do not completely control those symptoms.
- Trial name
- NCT00221416
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Depressive Disorder, Major
Abilify as an Adjunctive Treatment for Refractory Depression
This is a study of the effectiveness of adding Abilify (aripiprazole), an atypical antipsychotic medication, to ongoing selective serotonin reuptake inhibitor (SSRI) antidepressant treatment for depressed outpatients who are not…
- Trial name
- NCT00220636
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Schizophrenia
Aripiprazole Oral Acceptability Trial
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
- Trial name
- NCT00101569
- Testing
- Aripiprazole
- Where
- 7 sites in United States
- Volunteers
- 59 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar…
- Trial name
- SMART-M (NCT00545675)
- Testing
- Abilify(aripiprazole), Depakote (divalproate)
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia Relapse
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
- Trial name
- NCT03019887
- Testing
- reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
- Volunteers
- 139 people
- Sponsor
- Juntendo University
Autistic Disorder
A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder
- Trial name
- NCT01617447
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
European Long-acting Antipsychotics in Schizophrenia Trial
Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission.
- Trial name
- EULAST (NCT02146547)
- Testing
- Aripiprazole, Aripiprazole depot, Paliperidone
- Where
- 49 sites in Austria, Belgium and 14 more
- Volunteers
- 536 people
- Sponsor
- UMC Utrecht
Schizophrenia, Psychotic Disorders
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
- Trial name
- NCT00299702
- Testing
- Abilify, Risperidal Consta
- Volunteers
- 355 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression
FDA has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression.
- Trial name
- NCT00873795
- Testing
- aripiprazole , sertraline
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Chimei Medical Center
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
This study is designed to describe asenapine prescribing patterns in the United Kingdom (UK) during the post-approval period under conditions of usual practice.
- Trial name
- NCT01498770
- Testing
- Asenapine, Aripiprazole, Quetiapine
- Volunteers
- 42 people
- Sponsor
- Organon and Co
Schizophrenia
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders
Study to learn if the alternate formulation is effective in agitated schizophrenic patients
- Trial name
- NCT00036127
- Testing
- aripiprazole
- Where
- 16 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Schizophrenia
Antipsychotics and Risk of Hyperglycemic Emergencies
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02582736
- Testing
- Olanzapine, Risperidone, atypical antipsychotics (other)
- Where
- Canada
- Volunteers
- 725,489 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES